Development status of Chinese herbal extracts

International status: Traditional Chinese medicine and plant extracts have developed rapidly over the past few decades. In the 25 years prior to 2007, more than half of the registered drugs worldwide were derived from natural products or their synthetic derivatives.

Currently, there are nearly 20,000 herbal products in the US market alone, and about 20% of the population take herbal products. In 2013, the total sales of the US herbal dietary supplement market was US$6.032 billion, an increase of approximately 7.9%. According to the latest report of the American Institute of Botany (ABC) Herbalgram magazine, the sales of herbal tea in the United States reached 1.75 billion US dollars in 2014, an increase of 5.9% over 2013. 2. Domestic status: The Chinese plant extract industry is generally a Emerging industries are in the development stage. In recent years, the worldwide “return to nature” has been heating up, and plant extracts have received more and more attention from the pharmaceutical and food industries. It has become one of the fastest growing industries in China, and the market scale has developed by leaps and bounds. The inherent development potential.

After more than 20 years of accumulation and development, the Chinese medicine extraction industry has grown from more than 5 billion in 2005 to more than 16 billion in 2013. The enterprises engaged in planting have also grown from more than 200 in 2005 to the present. More than 3,000. However, production and operation are scattered. Some large pharmaceutical companies are involved. There are also a large number of enterprises specializing in extracts, but most of them are mainly small and medium-sized enterprises. Among them, there are more than 10 large and influential ones, such as Hongshengtang and Tian. Cheng, Jin Ke, etc.

China's plant extracts account for more than 80% of the industry's total exports. Exports are the main way to drive industry development. As of 2014, a total of 2,255 companies exported extracts from China, an increase of 479 compared with the same period last year. Among them, private enterprises accounted for 60.76% of exports, far ahead; “three-capital enterprises” followed closely, accounting for 28.54%. In 2001, the export value of Chinese plant extracts was only 191 million US dollars. Since 2007, the annual compound growth rate of industrial market sales revenue has reached 15.95%, and by 2010, exports have reached 815 million US dollars.

In 2011, China's exports of plant extracts amounted to 1.13 billion US dollars, becoming the first commodity category of Chinese medicine exports exceeding 1 billion US dollars, which became the main driving force for the export growth of Chinese medicine products. In 2012, the growth rate of foreign trade in plant extracts slowed down, with an export value of US$1.66 billion. In 2014, the export value was 1.41 billion US dollars. In 2014, exports reached a new high of 1.777 billion US dollars. The United States, Japan and India are the three traditional markets for China's export of extracts, with the three major markets accounting for 40.29% of total exports.

Among them, the United States exports 342 million US dollars, an increase of 9.29%; China's exports to the United States are mainly dietary supplements, including food additives such as stevia extract and mangosteen extract. In Japan and India, exports rose 21.38% and 47.05% year-on-year, with exports of $234 million and $139 million, respectively, accounting for 13.19% and 7.84%. China's exports to Japan are mainly rutin, Chinese herbal extracts and bilberry extract and other dietary supplements; the main export to India is pigment extracts such as pepper extract and marigold extract. In addition, ASEAN demand growth is evident every year. Exports increased by 74.81% year-on-year, especially in Indonesia and Singapore; exports reached US$116 million and US$49.026 million, respectively.